Dr. Steven Katzman, MD
Claim this profileMichigan Center of Medical Research
Studies Ulcerative Colitis
Studies Inflammatory Bowel Disease
2 reported clinical trials
1 drug studied
Affiliated Hospitals
Clinical Trials Steven Katzman, MD is currently running
ABX464
for Ulcerative Colitis
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
Recruiting1 award Phase 36 criteria
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106. All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg open label treatment arms (Part #2) depending on their clinical response at the end of induction. This study consists of a 44-week treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
Recruiting1 award Phase 3
More about Steven Katzman, MD
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Steven Katzman, MD has experience with
- ABX464
Breakdown of trials Steven Katzman, MD has run
Inflammatory Bowel Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven Katzman, MD specialize in?
Steven Katzman, MD focuses on Ulcerative Colitis and Inflammatory Bowel Disease. In particular, much of their work with Ulcerative Colitis has involved treating patients, or patients who are undergoing treatment.
Is Steven Katzman, MD currently recruiting for clinical trials?
Yes, Steven Katzman, MD is currently recruiting for 2 clinical trials in Farmington Hills Michigan. If you're interested in participating, you should apply.
Are there any treatments that Steven Katzman, MD has studied deeply?
Yes, Steven Katzman, MD has studied treatments such as ABX464.
What is the best way to schedule an appointment with Steven Katzman, MD?
Apply for one of the trials that Steven Katzman, MD is conducting.
What is the office address of Steven Katzman, MD?
The office of Steven Katzman, MD is located at: Michigan Center of Medical Research, Farmington Hills, Michigan 48334 United States. This is the address for their practice at the Michigan Center of Medical Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.